"If MSB doesn't get its BLA what then for CYP? Not handled in the report."
Classic JB crap.
The report addresses two other near-term catalysts (DFU results Jan 2025, GvHD results late 2025/early 2026), while acknowledging but not going into detail about at least two more (Knee OA results H1 2026, Renal transplantation results H1 2025). Let alone deals for 3 of the 4.
In the short term, MSB approval will result in more retail interest in this part of the biotech sector. That is a fact and there are numerous examples of this occurring in other sectors (notably lithium from H2 2020, with money pouring from gains in large cap to small caps across the next 24 months). If MSB doesn't get approval, it won't attract new buyers to CYP in the short term. But if they produce good clinical data then it will add value in their own right, as partnerships will become more likely.
JB post value - zero in my opinion.
CYP Price at posting:
21.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)